Kornimate/medical-research-clean huggingface dataset:
post-covid 19 patients undergoing surgery

Conditions: Covid19

Summary: more and more patients are undergoing elective surgery after sars-cov-2 infection, and little is known about the residual pulmonary changes in these patients after infection and postoperative pulmonary complications. so, we propose an observational study comparing postcovid-19 patients with normal population (control group) undergoing surgery.

the most common lung complications of severe covid-19 are pneumonia and hypoxemic respiratory failure/ards. manifestations of lung inflammation or fibrosis were also observed in late stages of covid-19 causing respiratory sequelae. fibrous lesions may form during the healing of pulmonary chronic inflammation or proliferative diseases, with gradual replacement of cellular components by scar tissues indicating a poor outcome of covid-19. ultrasound allows to stratify the severity of lung damage and combined with the clinic, can help estimate the patient's prognosis and support therapeutic decision-making. on the other hand, pulmonary inflammatory processes and fibrosis are responsible for a decrease in respiratory distensibility or pulmonary compliance. pulmonary parenchyma distensibility is known as static distensibility or compliance and it´s calculated by mechanical ventilators during general anesthesia. there are no studies that determine the results of lung ultrasound and pulmonary compliance in preoperative and intraoperative period respectively in postcovid patients, and the postoperative complications of postcovid patients are poorly understood.

Eligibility criteria:
control group inclusion criteria.: -patients over the age of 18 who did not have covid-19 and who are going to undergo scheduled surgery exclusion criteria: * patients under the age of 18. * unstable patients in shock * patients in current state of pulmonary hypertension or heart failure * patients with moderate-severe pulmonary pathology prior to surgery. * patients previously surgery for chest surgery * patients in current state of respiratory infection post-covid group inclusion criteria -post-covid-19 patients (confirmed by pcr) \>18 years undergoing scheduled surgery without pulmonary disease prior to sars-cov-2 infection, that at the time of surgery present negative pcr and absence of clinic due to sars-cov-2 infection. exclusion criteria: * patients under the age of 18 * unstable patients in shock * patients in current state of pulmonary hypertension or heart failure * patients with moderate-severe pulmonary pathology prior to sars-cov-2. * patients previously surgery for chest surgery * patients in current state of respiratory infection

Keywords: post-covid patients pulmonary sequelae postoperative complications
analysis of lipid biomarkers of exposure and host response

Conditions: Cigarette Smoking

Summary: the purpose of this prospective, open-label, clinical trial is to establish the feasibility and validity of exhaled breath condensate (ebc) biomarkers for use in studies designed to evaluate harm reduction strategies of smoking. this will be accomplished by measuring selected markers in ebc believed related to the pathogenesis of lung disease before and after a smoking cessation intervention.

twenty subjects will be accrued in three groups based on smoking habit: 10-20, 20-30 and \>30 cigarettes/day. eligibility criteria include male and female cigarette smokers ≥19 years of age, who are able to give informed consent, able to exhale into eco screen instrument for 15-20 minutes. all must be willing to make a serious quit attempt and be willing to use nicotine replacement therapy. subjects will be excluded if any of the following are present: regular use of anti-inflammatory medication; presence of any inflammatory disease of the respiratory tract including moderate or worse copd (fev1 \< 80% predicted and fev1/fvc ratio \< 0.7). subjects with normal lung function who meet criteria for diagnosis of chronic bronchitis will be excluded. subjects with stable medical conditions, excluding inflammatory lung disease, will be permitted to participate, providing anti-inflammatory therapies are not used regularly and providing there has been no change in their clinical status in the two months prior to beginning the study. upon entering into the study, subjects will establish a quit date and will be treated with nicotine replacement therapy (nrt) products based on individual preference and will receive smoking cessation counseling. they will then be seen at 12 visits over the course of 25 weeks. evaluations will include vital signs, interval smoking history, food frequency questionnaire, exhaled carbon monoxide, blood drawn for chemistry and cbc, peripheral blood harvested and serum aliquoted and saved for future biochemical analysis, urine sample for isoprostane, pregnancy test for females, and exhaled breath condensate. some visits may also include spirometry with and with out bronchodilators, 24 hour urine collections for nnal and nnal-glc quantification, health status assessed using st. george's respiratory questionnaire, the functional assessment of chronic illness therapy - fatigue, the leicester cough questionnaire, the clinical copd questionnaire and smoking related symptoms assessed using the breathlessness, cough, and sputum scale.

Eligibility criteria:
inclusion criteria: * smoke at least 5 pack years * have a stable smoking habit for 3 months * be willing to make a serious quit attempt and * be able to use nicotine replacement therapy exclusion criteria: * regular use of an anti-inflammatory medication * presence of an inflammatory lung disease * unstable medical condition

Keywords: smoking reduction inflammation harm reduction lipid biomarkers
mowi qualitative assessment

Conditions: Obesity

Summary: this qualitative study seeks to assess whether mobile health technologies are helpful for older adults. it is the first in a series of four studies whose overarching goal is to conduct a program of pilot research aimed at developing and evaluating a technology-assisted wellness intervention for older adults with obesity who may or may not live in a rural area.

this study is designed and conducted as a series of eighteen individual semi-structured interviews and four focus group discussions. there are three participant groups: 1) older adults (age ≥ 65 years) with diagnosed obesity, 2) primary care clinicians who care for older adults, and 3) community leaders. focus group discussions are conducted with the older adult cohort only.

Eligibility criteria:
inclusion criteria: * age ≥65 years; * body mass index (bmi) ≥ 30kg/m\^2; * waist circumference ≥88cm in females or ≥102cm in males exclusion criteria: * severe mental or life-threatening illness * dementia * substance use * history of bariatric surgery * suicidal ideation * unable to perform measures * reside in a nursing home

Keywords: frail elderly telemedicine obesity rural health health promotion
safety and efficacy of g17dt immunogen combined with gemcitabine vs. gemcitabine in the treatment of advanced pancreatic carcinoma

Conditions: Pancreatic Cancer

Summary: this study will test whether the g17dt immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for pancreatic cancer.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of pancreatic adenocarcinoma and unsuitable for pancreatic tumor resection * life expectancy of at least 3 months * functional status by karnofsky index of at least 70 exclusion criteria: * prior treatment with chemotherapy, radiotherapy, or anti-cancer immunotherapy * chronic use of corticosteroids, except for inhaled corticosteroids used for asthma or chronic obstructive pulmonary disease * immunodeficiency * bone marrow transplant within past year * brain metastasis

Keywords: pancreatic cancer g17dt gemcitabine
salt supplementation in gitelman syndrome

Conditions: Gitelman Syndrome

Summary: the purpose of this study is to determine the effect of salt (nacl) supplementation on serum potassium and clinical signs and symptoms in patients with gitelman syndrome.

single subject multiple randomized double-blinded multi-crossover placebo-controlled trials (n-of-1 trials) will be performed. participants will enroll the study after giving written informed consent. the individual trials will consist of 3 treatment blocks which each contain a 4-week treatment period of salt supplementation (12 grams of nacl) and a 4-week treatment period of placebo, in a randomized, blinded order. after each period of 4 weeks, outcomes measures will be measured.

Eligibility criteria:
inclusion criteria: * genetically-proven, symptomatic gitelman syndrome * written informed consent exclusion criteria: * inability to discontinue potassium-sparing diuretics, mineralocorticoid antagonists and nsaids; this means inability to reach a potassium level of 2.5 mmol/l or higher with maximally tolerable potassium supplementation after discontinuation of potassium-sparing diuretics * pregnancy
chain_brazilian registry of congenital heart disease intervention and angiography

Conditions: Congenital Heart Disease; Cardiac Catheterization; Brazilian Electronic Registration; Catheterization Diagnostic or Therapeutic

Summary: design: observational - cross study with followed up for 30 days. the primary objective is to realize a record that reflects a national overview of the role of cardiac catheterization in patients with congenital heart disease in hospitals distributed by geographic density of each region of brazil.

patients admitted in the hemodynamic sector with diagnosed or suspected congenital cardiopathy and undergoing diagnostic or therapeutic cardiac catheterization. participants release the data in (e-crf) electronics system. sample: 2000 records.

Eligibility criteria:
inclusion criteria: * patients admitted to the hemodynamic sector with diagnosed or suspected congenital cardiopathy and undergoing diagnostic or therapeutic cardiac catheterization. exclusion criteria: * patients undergoing hybrid approach to intervention, with the aid of cardiac surgery to realization of cardiac catheterization.

Keywords: congenital heart disease cardiac catheterization brazilian electronic registration
immature myeloid cells in respiratory syncytial virus bronchioliltis

Conditions: Bronchiolitis

Summary: the investigators hypothesize that respiratory syncytial virus (rsv) infection may influence the population of lung immature myeloid cells and dendritic cells in a way that will impair their ability to invoke an effective immune response and lead to prolonged inflammation, angiogenesis and scarring. this may lead in turn to disturbed lung function. our aim is to determine the presence and phenotype of immature myeloid cells present in respiratory secretions of children with rsv bronchiolitis as compared to non-rsv bronchiolitis and healthy controls.


Eligibility criteria:
inclusion criteria: * bronchiolitis exclusion criteria: * chronic disease
observational study for left main disease treatment

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to observe clinical courses for long-term in patients with unprotected lmca disease and to evaluate comparative results of medical treatment, coronary stenting with drug-eluting stents, and cabg for the treatment of an unprotected lmca stenosis in the "real world" daily practice.

this study is a multicenter, large clinical registry to evaluate comparative outcomes of medical therapy, pci with des, or cabg for patients with unprotected lmca stenosis in the asia-pacific, as recorded in the main-iris registry. data will be prospectively collected on approximately 5000 subjects who diagnosed lm disease (\>50% by visual estimation) at approximately 65 centers in korea and asia-pacific region. brief study design is as depicted in the following figure

Eligibility criteria:
inclusion criteria: * significant unprotected left main stenosis (\>50% by visual estimation) * the lmca is considered unprotected if there are no patent coronary artery bypass grafts to the left anterior descending artery or the left circumflex artery. * no limitation of clinical or lesion characteristics * age \>18 years * the patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate institutional review board/ethics committee of the respective clinical site. exclusion criteria: * protected left main stenosis

Keywords: left main
advanced ehealth for chronic obstructive pulmonary disease (copd) in colorado

Conditions: Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease (copd) is the 4th leading cause of death in the united states, affects 24 million people and is responsible for up to $32 billion annually in direct and indirect health care costs. based upon these national copd prevalence data, we estimate that 483,000 coloradans have copd (193,000 diagnosed and 290,000 undiagnosed), and that the care of these patients costs up to $490 million annually. therefore, to alter the impact of copd on the state and people of colorado, we propose to introduce a telephone-dependent, internet-supported, self-monitoring "ehealth" management system in both urban and rural colorado settings in order to decrease healthcare utilization, improve the management of copd based upon current national guidelines, improve quality of life, reduce health care costs decrease copd exacerbations. we base this program on a successful clinical pilot study, performed at the university of colorado hospital (uch) during 2004-2005, which demonstrated dramatic improvements in quality of life and decreased health care costs. we propose to enroll patients with advanced copd, or a history of copd exacerbations, because these are the patients with the highest healthcare costs, the greatest disability, and the highest mortality. the ultimate goal of this project is to demonstrate the feasibility and efficacy of this proactive management strategy as it is disseminated throughout urban and rural colorado. in this first phase we will target two denver metro sites, uch and kaiser-permanente (kp), and rural sites (to be determined). we chose these urban sites because of their strong interest in enacting the ehealth program, because of their organized systems of healthcare delivery and because of the numbers of copd patients that they serve. we are particularly enthusiastic about the application of this technology to rural, underserved areas, because this approach has the potential to dramatically improve delivery of healthcare to a large portion of colorado that is chronically plagued by inadequate health care networks and lack of specialty care. more broadly, we are enthusiastic about the prospect that ehealth programs may hold the potential to improve healthcare delivery for many chronic illnesses, in addition to copd.


Eligibility criteria:
inclusion criteria: * copd diagnosis per gold guidelines * airflow obstruction on spirometry defined as an fev1/fvc less than or equal to 70% and an fev1 less than or equal to 50% predicted, or an fev1 greater than 50% predicted with a history of a copd exacerbation within the previous year. * standard telephone access * us citizen and colorado resident exclusion criteria: * asthma * co-existing conditions that are likely to cause death within two years, cxr evidence of interstitial lung disease or other pulmonary diagnoses at the time of enrollment, end-stage liver disease, end-stage renal disease, end-stage muscle disease, hiv disease or dementia.

Keywords: chronic obstructive pulmonary disease telemedicine copd
safety profile following inactivated covid-19 vaccine in healthy adults aged >18 years in indonesia

Conditions: Safety Issues

Summary: the aim of this study is evaluating safety profile of covid-19 vaccine in healthy adults aged \>18 years in indonesia.

to assess any serious systemic reaction within 30 minutes after covid-19 vaccine immunization. to assess systemic reaction after covid-19 vaccine immunization. to assess local reaction after covid-19 vaccine immunization. to assess any serious adverse event after covid-19 vaccine immunization.

Eligibility criteria:
inclusion criteria: * clinically healthy adults aged \> 18 years. * subjects have been informed properly regarding the study and signed the informed consent form. * subjects will commit to comply with the instructions of the investigator and the schedule of the trial. exclusion criteria: * subjects concomitantly enrolled or scheduled to be enrolled in another trial. * evolving mild, moderate or severe illness, especially infectious disease or fever (body temperature ≥37.5℃, measured with thermometer). * women who are lactating, pregnant or planning to become pregnant during the study period. * history of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection. * subjects who have any history of confirmed or suspected immunosuppressive or immunodeficient state, or received in the previous 4 weeks a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products or long-term corticosteroid therapy (\> 2 weeks)). * subjects receive any vaccination within 1 month before and after ip immunization. * subjects plan to move from the study area before the end of study period.
impact of covid-19 pandemic on children with neuromuscular disease and their parents in turkey: parent perspective

Conditions: Neuromuscular Diseases

Summary: parents of children with neuromuscular disease have been already at risk of depression, anxiety and burden. additionally, the daily lives of children with neuromuscular disease and their parents have been significantly affected by the covid-19 pandemic. therefore, this study investigated parents' perspective on the effect of the covid-19 pandemic on children with neuromuscular diseases and themselves.

the 55-item survey created by the researchers was applied online to determine the psychological and physical effects of covid-19 on neuromuscular patients and their families. this survey also included the content of the 9-item caregiver covid-19 limitations scale (ccls-9).

Eligibility criteria:
inclusion criteria: * taking care for a child with nmd whose age was between 0-18 years, * having the ability to read and write turkish language, * having access to phone or e-mail, * being volunteer. exclusion criteria: * having a child who have an additional diagnosis besides nmd and taking care of any other person in the family.
immunomagnetic detection of cancer cells in pleural effusion in lung cancer patients as additional staging and prognostic tool

Conditions: Lung Cancer

Summary: pleural effusion in lung cancer patients is one of the symptoms of metastatic disease that is inoperable and cannot be treated. identification of cancer cells in the pleural effusion of lung cancer patients is a cytological test and serves as an initial diagnosis. these cells can then be used to prepare a cell block for staining and further tests. in some research despite clinical suspicions, the cytological diagnosis is negative, due to the specimen containing too few cells or damage to the cells whilst the specimen is processed. a new method of identifying rare cells in a fluid is by immunomagnetic separation. using this method, an antigen binds to proteins in the cell wall that are unique to tumor cells. when the fluid is passed through a magnetic field, separation occurs of the cells with the magnetic tags from the remainder of the cells. the separated cells can then be stained or cultured. the currently approved method of immunomagnetic detection has been approved for clinical use in patients with breast cancer, cancer of the intestines and prostate cancer. an israeli biotech company has developed an advanced technology that allows identification of a larger number of cells without causing morphological damage to the cells. the purpose of the current study is to examine the technique of immunomagnetic separation in pleural effusion of lung cancer patients in comparison to the cytological tests. in the future it is hoped that a larger number of patient samples will be included and further characterization of the cells will be possible to be compared to the clinical and cytological characteristics.


Eligibility criteria:
inclusion criteria: * age 18 and over * lung cancer patients in the lung department or oncology department with spread to the pleural cavity. exclusion criteria: * under age 18
a phase 1/2 study to investigate crb-701 in solid tumors

Conditions: Solid Tumor, Adult

Summary: the goal of this clinical trial is to define a safe and effective dose of crb-701 for participants with solid tumors that are expressing a protein called nectin-4. the main questions it aims to answer are: what is the the safe and effective dose of crb-701 when used alone? what cancers can be treated effectively with crb-701? participants will be asked to attend clinic and be given a intravenous infusion of crb-701 on its own. they will have blood tests and other assessments to measure whether crb-701 will have ct or mri scans to measure the effect on tumors.

this is a three-part open-label, phase 1/2 clinical trial designed to evaluate the safety, pk, and efficacy of crb-701 in participants with advanced solid tumors expressing nectin-4. part a will include solid tumor types known to express nectin-4. dose escalation will be guided by the bayesian optimal interval (boin) design to determine the mtd of crb-701. four (4) dose groups are pre-determined. dose escalation/de-escalation decisions are made based on the occurrence of dlt. part b will determine the rp2d of crb-701 by evaluating two dose levels of crb-701 alone and in combination with anti-pd-1 by using a time-to-event bayesian optimal phase 2 (top) study design to optimize the dose of crb-701 in one or more separate cohorts of participants with nectin-4-positive tumors. during part c, the rp2d dose of crb-701 alone or combined with anti-pd-1 will be evaluated in five planned expansion cohorts using simon's optimal two-stage design.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of select advanced or metastatic nectin-4 expressing solid tumors that have progressed following at least one line of therapy or have no other standard therapy with proven clinical benefit. exclusion criteria: * active of uncontrolled cns metastases * history of solid tumors other than the diseases under study * history of and/or current cardiovascular events or conditions in the previous 6 months * pre-existing \>/= grade 2 neuropathy * hemoglobin a1c (hba1c) \>/= 8%, uncontrolled diabetes mellitus or know diabetic neuropathy * active ocular disease at baseline * chronic severe liver disease or live cirrhosis * interstitial lung disease or pneumonitis within 6 months on initiating treatment on study * other significant cormorbidities.

Keywords: nectin-4